Oral application of freeze-dried yeast particles expressing the PCV2b Cap protein on their surface induce protection to subsequent PCV2b challenge in vivo

Vaccine

Volumn 33, Issue 46, 2015, Pages 6199-6205

  Patterson, Robert ^a   Eley, Thomas ^a   Browne, Christopher ^a   Martineau, Henny M ^a   Werling, Dirk ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Freeze dried; IFN ; IFN ; Oral; ORF2; PCV2b; Yeast

Indexed keywords

ALPHA INTERFERON; CAPSID PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; INTERLEUKIN 1BETA; PORCINE CIRCOVIRUS 2B CAP PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; CYTOKINE; RECOMBINANT VACCINE; SECRETORY IMMUNOGLOBULIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FECES; FREEZE DRYING; GENE DOSAGE; ILEUM; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPHOID TISSUE; NONHUMAN; PIG; POLYMERASE CHAIN REACTION; PORCINE CIRCOVIRUS 2; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECTUM TEMPERATURE; SACCHAROMYCES CEREVISIAE; SERUM; SURFACE PROPERTY; VACCINATION; VIREMIA; VIRUS LOAD; VIRUS STRAIN; YEAST CELL; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; CHEMISTRY; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; DRIED YEAST; GENETICS; IMMUNOLOGY; LYMPHATIC SYSTEM; ORAL DRUG ADMINISTRATION; SWINE DISEASES; VIROLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CIRCOVIRIDAE INFECTIONS; CIRCOVIRUS; CYTOKINES; FECES; ILEUM; IMMUNOGLOBULIN A, SECRETORY; LYMPHATIC SYSTEM; SERUM; SWINE; SWINE DISEASES; VACCINES, SYNTHETIC; VIRAL LOAD; VIRAL VACCINES; YEAST, DRIED;

EID: 84946594286     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.10.003     Document Type: Article

References (40)

1. Allan G.M., Mc Neilly F., Meehan B.M., Kennedy S., Mackie D.P., Ellis J.A., et al. Isolation and characterisation of circoviruses from pigs with wasting syndromes in Spain, Denmark and Northern Ireland. Vet Microbiol 1999, 66:115-123.
2. Mavrommatis B., Offord V., Patterson R., Watson M., Kanellos T., Steinbach F., et al. Global gene expression profiling of myeloid immune cell subsets in response to in vitro challenge with porcine circovirus 2b. PLoS ONE 2014, 9:e91081.
3. Marcekova Z., Psikal I., Kosinova E., Benada O., Sebo P., Bumba L. Heterologous expression of full-length capsid protein of porcine circovirus 2 in Escherichia coli and its potential use for detection of antibodies. J Virol Methods 2009, 162:133-141.
4. Beach N.M., Meng X.J. Efficacy and future prospects of commercially available and experimental vaccines against porcine circovirus type 2 (PCV2). Virus Res 2012, 164:33-42.
5. Gilligan C.A., Li Wan Po A. Oral enteric vaccines - clinical trials. J Clin Pharm Ther 1991, 16:309-335.
6. Sedgmen B.J., Meeusen E.N., Lofthouse S.A. Alternative routes of mucosal immunization in large animals. Immunol Cell Biol 2004, 82:10-16.
7. Bucarey S.A., Noriega J., Reyes P., Tapia C., Saenz L., Zuniga A., et al. The optimized capsid gene of porcine circovirus type 2 expressed in yeast forms virus-like particles and elicits antibody responses in mice fed with recombinant yeast extracts. Vaccine 2009, 27:5781-5790.
8. Alarcon P., Velasova M., Mastin A., Nevel A., Stark K.D., Wieland B. Farm level risk factors associated with severity of post-weaning multi-systemic wasting syndrome. Prev Vet Med 2011, 101:182-191.
9. Patterson R., Nevel A., Diaz A.V., Martineau H.M., Demmers T., Browne C., et al. Exposure to environmental stressors result in increased viral load and further reduction of production parameters in pigs experimentally infected with PCV2b. Vet Microbiol 2015, 177:261-269.
10. Franzusoff A., Duke R.C., King T.H., Lu Y., Rodell T.C. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 2005, 5:565-575.
11. Huang H., Ostroff G.R., Lee C.K., Specht C.A., Levitz S.M. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio 2010, 1.
12. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001, 7:625-629.
13. Allnutt F.C., Bowers R.M., Rowe C.G., Vakharia V.N., LaPatra S.E., Dhar A.K. Antigenicity of infectious pancreatic necrosis virus VP2 subviral particles expressed in yeast. Vaccine 2007, 25:4880-4888.
14. Sun H., Wang L., Wang T., Zhang J., Liu Q., Chen P., et al. Display of Eimeria tenella EtMic2 protein on the surface of Saccharomyces cerevisiae as a potential oral vaccine against chicken coccidiosis. Vaccine 2014, 32:1869-1876.
15. Shin M.K., Yoo H.S. Animal vaccines based on orally presented yeast recombinants. Vaccine 2013, 31:4287-4292.
16. Dvorak C.M., Lilla M.P., Baker S.R., Murtaugh M.P. Multiple routes of porcine circovirus type 2 transmission to piglets in the presence of maternal immunity. Vet Microbiol 2013, 166:365-374.
17. Wieland B., Werling D., Nevel A., Rycroft A., Demmers T.G., Wathes C.M., et al. Porcine circovirus type 2 infection before and during an outbreak of postweaning multisystemic wasting syndrome on a pig farm in the UK. Vet Rec 2012, 170:596.
18. Patterson R., Nerren J., Kogut M., Court P., Villarreal-Ramos B., Seyfert H.M., et al. Yeast-surface expressed BVDV E2 protein induces a Th1/Th2 response in naive T cells. Dev Comp Immunol 2012, 37:107-114.
19. Signer E.N., Jeffreys A.J., Licence S., Miller R., Byrd P., Binns R. DNA profiling reveals remarkably low genetic variability in a herd of SLA homozygous pigs. Res Vet Sci 1999, 67:207-211.
20. Grierson S.S., King D.P., Wellenberg G.J., Banks M. Genome sequence analysis of 10 Dutch porcine circovirus type 2 (PCV-2) isolates from a PMWS case-control study. Res Vet Sci 2004, 77:265-268.
21. O'Neill K.C., Shen H.G., Lin K., Hemann M., Beach N.M., Meng X.J., et al. Studies on porcine circovirus type 2 vaccination of 5-day-old piglets. Clin Vaccine Immunol 2011, 18:1865-1871.
22. Opriessnig T., Thacker E.L., Yu S., Fenaux M., Meng X.J., Halbur P.G. Experimental reproduction of postweaning multisystemic wasting syndrome in pigs by dual infection with Mycoplasma hyopneumoniae and porcine circovirus type 2. Vet Pathol 2004, 41:624-640.
23. Bilusic M., Heery C.R., Arlen P.M., Rauckhorst M., Apelian D., Tsang K.Y., et al. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother 2014, 63:225-234.
24. Haller A.A., Lauer G.M., King T.H., Kemmler C., Fiolkoski V., Lu Y., et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007, 25:1452-1463.
25. Kim H.J., Lee J.Y., Kang H.A., Lee Y., Park E.J. Oral immunization with whole yeast producing viral capsid antigen provokes a stronger humoral immune response than purified viral capsid antigen. Lett Appl Microbiol 2014, 58:285-291.
26. Lu Y., Bellgrau D., Dwyer-Nield L.D., Malkinson A.M., Duke R.C., Rodell T.C., et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res 2004, 64:5084-5088.
27. Fort M., Sibila M., Nofrarias M., Perez-Martin E., Olvera A., Mateu E., et al. Evaluation of cell-mediated immune responses against porcine circovirus type 2 (PCV2) Cap and Rep proteins after vaccination with a commercial PCV2 sub-unit vaccine. Vet Immunol Immunopathol 2012, 150:128-132.
28. Rodriguez-Arrioja G.M., Segales J., Calsamiglia M., Resendes A.R., Balasch M., Plana-Duran J., et al. Dynamics of porcine circovirus type 2 infection in a herd of pigs with postweaning multisystemic wasting syndrome. Am J Vet Res 2002, 63:354-357.
29. Sibila M., Calsamiglia M., Segales J., Blanchard P., Badiella L., Le Dimna M., et al. Use of a polymerase chain reaction assay and an ELISA to monitor porcine circovirus type 2 infection in pigs from farms with and without postweaning multisystemic wasting syndrome. Am J Vet Res 2004, 65:88-92.
30. Trible B.R., Ramirez A., Suddith A., Fuller A., Kerrigan M., Hesse R., et al. Antibody responses following vaccination versus infection in a porcine circovirus-type 2 (PCV2) disease model show distinct differences in virus neutralization and epitope recognition. Vaccine 2012, 30:4079-4085.
31. Fort M., Olvera A., Sibila M., Segales J., Mateu E. Detection of neutralizing antibodies in postweaning multisystemic wasting syndrome (PMWS)-affected and non-PMWS-affected pigs. Vet Microbiol 2007, 125:244-255.
32. Fort M., Fernandes L.T., Nofrarias M., Diaz I., Sibila M., Pujols J., et al. Development of cell-mediated immunity to porcine circovirus type 2 (PCV2) in caesarean-derived, colostrum-deprived piglets. Vet Immunol Immunopathol 2009, 129:101-107.
33. Koinig H.C., Talker S.C., Stadler M., Ladinig A., Graage R., Ritzmann M., et al. PCV2 vaccination induces IFN-gamma/TNF-alpha co-producing T cells with a potential role in protection. Vet Res 2015, 46:20.
34. Engle T.B., Jobman E.E., Moural T.W., McKnite A.M., Bundy J.W., Barnes S.Y., et al. Variation in time and magnitude of immune response and viremia in experimental challenges with Porcine circovirus 2b. BMC Vet Res 2015, 10:286.
35. Kreikemeier C.A., Engle T.B., Lucot K.L., Kachman S.D., Burkey T.E., Ciobanu D.C. Genome-wide analysis of TNF-alpha response in pigs challenged with porcine circovirus 2b. Anim Genet 2015, 46:205-208.
36. Liu G., Yang G., Guan G., Zhang Y., Ren W., Yin J., et al. Effect of dietary selenium yeast supplementation on porcine circovirus type 2 (PCV2) infections in mice. PLOS ONE 2015, 10:e0115833.
37. Fort M., Sibila M., Nofrarias M., Perez-Martin E., Olvera A., Mateu E., et al. Porcine circovirus type 2 (PCV2) Cap and Rep proteins are involved in the development of cell-mediated immunity upon PCV2 infection. Vet Immunol Immunopathol 2010, 137:226-234.
38. Seo H.W., Han K., Park C., Chae C. Clinical, virological, immunological and pathological evaluation of four porcine circovirus type 2 vaccines. Vet J 2014, 200:65-70.
39. Seo H.W., Oh Y., Han K., Park C., Chae C. Reduction of porcine circovirus type 2 (PCV2) viremia by a reformulated inactivated chimeric PCV1-2 vaccine-induced humoral and cellular immunity after experimental PCV2 challenge. BMC Vet Res 2012, 8:194.
40. Jiang T., Singh B., Li H.S., Kim Y.K., Kang S.K., Nah J.W., et al. Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan. Biomaterials 2014, 35:2365-2373.